Iterum Therapeutics’ (ITRM) Buy Rating Reiterated at HC Wainwright

Share on StockTwits

HC Wainwright reaffirmed their buy rating on shares of Iterum Therapeutics (NASDAQ:ITRM) in a research report sent to investors on Thursday, AnalystRatings.com reports. They currently have a $17.00 target price on the stock.

ITRM has been the topic of several other reports. Zacks Investment Research upgraded Iterum Therapeutics from a sell rating to a hold rating in a research note on Wednesday, July 17th. Royal Bank of Canada dropped their target price on Iterum Therapeutics to $17.00 and set an outperform rating on the stock in a research note on Wednesday, May 15th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Iterum Therapeutics has a consensus rating of Buy and a consensus price target of $15.75.

Shares of ITRM stock opened at $6.76 on Thursday. Iterum Therapeutics has a 1-year low of $4.70 and a 1-year high of $11.22. The stock’s fifty day moving average price is $6.65 and its 200 day moving average price is $6.84. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.10 and a quick ratio of 4.36. The company has a market cap of $93.53 million, a price-to-earnings ratio of -0.95 and a beta of 2.05.

Iterum Therapeutics (NASDAQ:ITRM) last announced its earnings results on Wednesday, August 14th. The company reported ($1.93) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.50) by ($0.43). Iterum Therapeutics had a negative return on equity of 136.21% and a negative net margin of 11,956.64%. As a group, equities research analysts anticipate that Iterum Therapeutics will post -6.74 earnings per share for the current year.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.

Recommended Story: Front-End Load

Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.